Triple-negative breast cancer, stage 2A, has the possibility of curing the lesion and requires regular treatment by the patient under the guidance of a doctor. Triple-negative breast cancer is called triple-negative breast cancer when the patient is negative for estrogen receptor (ER), progesterone receptor (PR) and proto-oncogene Her-2 in immunohistochemical examination of the diseased tissue. This type of breast cancer lesion has a relatively poor prognosis. Stage 2 should be T2 stage, which refers to the TNM stage of breast cancer, indicating that the diameter of the cancer is greater than 2 centimeters but less than or equal to 5 centimeters. T2A stage is a sub-stage of T2 stage, suggesting that the patient is still in the early stage of the disease. According to the patient’s pathological type and the stage of disease, although the degree of malignancy is high, the patient is in the early stage of the disease, so the patient should take radical surgery to remove the lesion and clear the lymph nodes, and then according to the pathological type, immunohistochemistry result and gene test result, the patient should take the subsequent radiotherapy and targeted drug treatment to enhance the therapeutic effect as much as possible, so that the patient can be cured of the lesion. It is then necessary for the patient to be treated under the guidance of the doctor, and must not adjust the treatment program at will, not to mention not to believe in biased prescriptions and local remedies, so as not to affect the treatment.